<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Linezolid (LZD) is the first oxazolidinone antibiotic that is effective against drug-resistant <z:mp ids='MP_0001796'>gram-positive</z:mp> organisms </plain></SENT>
<SENT sid="1" pm="."><plain>Hematological toxicities such as <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0001903'>anemia</z:hpo>, and <z:mp ids='MP_0000221'>leukocytopenia</z:mp> are common in LZD therapy </plain></SENT>
<SENT sid="2" pm="."><plain>However, LZD-induced pure red cell <z:mpath ids='MPATH_58'>aplasia</z:mpath> (PRCA) is very rare </plain></SENT>
<SENT sid="3" pm="."><plain>A 56-year-old man with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> underwent allogeneic bone marrow transplantation from a human leukocyte antigen-matched and ABO blood type-matched unrelated male donor </plain></SENT>
<SENT sid="4" pm="."><plain>He had <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e> caused by Staphylococcus epidermidis after engraftment of neutrophils and red blood cells </plain></SENT>
<SENT sid="5" pm="."><plain>We first administered <z:chebi fb="0" ids="28001">vancomycin</z:chebi>, but then changed to intravenous LZD because of kidney damage </plain></SENT>
<SENT sid="6" pm="."><plain>Two weeks after LZD therapy, the patient's <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> and reticulocyte levels were 6.8 g/dL and 0.3%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Bone marrow examination revealed red blood cell <z:mpath ids='MPATH_58'>aplasia</z:mpath> (myeloid/erythroid ratio was 402) </plain></SENT>
<SENT sid="8" pm="."><plain>The patient showed rapid recovery of <z:mpath ids='MPATH_458'>normal</z:mpath> erythropoiesis within 2 weeks of LZD cessation </plain></SENT>
<SENT sid="9" pm="."><plain>It is important to be aware of the hematological effects associated with LZD in the setting of stem cell transplantation,particularly for those with pre-existing <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo>, and those receiving concomitant drugs that produce bone marrow suppression </plain></SENT>
<SENT sid="10" pm="."><plain>We advocate that a reticulocyte count be performed periodically for detecting bone marrow suppression, including PRCA, during LZD therapy </plain></SENT>
</text></document>